Literature DB >> 6754328

[Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study].

H Rasche, F Haghou, W Gaus, M Dietrich, D Hoelzer, H Pflieger, E Kurrle, G Pindur, E Seifried, H Heimpel.   

Abstract

A randomized and controlled study was undertaken to test whether substitution with factor XIII concentrates influences the clinical course in patients with acute leukaemia and acquired factor XIII deficiency (less than or equal to 60%). A control group of 31 patients was compared with a factor XIII-treated group of 29 patients. Partial factor XIII deficiency was successfully corrected by substitution. On the other hand, there was no statistically significant difference between the two patient groups in the frequency and severity of bleeding complications, transfusion requirements, and the number of remissions. Undesirable side-effects as a result of substitution treatment were not observed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6754328     DOI: 10.1055/s-2008-1070225

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  6 in total

Review 1.  [Therapy with blood products].

Authors:  S Petros
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-01-29       Impact factor: 0.840

2.  Hyperfibrinolysis and acquired factor XIII deficiency in newly diagnosed pediatric malignancies.

Authors:  Verena Wiegering; Oliver Andres; Paul G Schlegel; Frank Deinlein; Matthias Eyrich; Alexander Sturm
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

3.  Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Behaviour before and during treatment according to Protocol I of the Cooperative Leukaemia Study COALL-80.

Authors:  M Reitz; G Witzke; R Egbring; P Gutjahr
Journal:  Klin Wochenschr       Date:  1984-12-17

Review 4.  Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.

Authors:  Michael Desborough; Lise J Estcourt; Carolyn Doree; Marialena Trivella; Sally Hopewell; Simon J Stanworth; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2016-08-22

5.  Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia.

Authors:  Jez Fabes; Susan J Brunskill; Nicola Curry; Carolyn Doree; Simon J Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2018-12-24

6.  De Novo Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (MYC/BCL-2) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency.

Authors:  Dina Sameh Soliman; Ahmad Al-Sabbagh; Feryal Ibrahim; Shehab Fareed; Mohamed Talaat; Mohamed A Yassin
Journal:  J Hematol (Brossard)       Date:  2017-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.